Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 6/2016

Open Access 01-12-2016 | Case Report

Zika virus infection in 18 travellers returning from Surinam and the Dominican Republic, The Netherlands, November 2015–March 2016

Authors: Janneke W. Duijster, Abraham Goorhuis, Perry J. J. van Genderen, Leo G. Visser, Marion P. Koopmans, Johan H. Reimerink, Martin P. Grobusch, Annemiek A. van der Eijk, Johannes H. C. T. van den Kerkhof, Chantal B. Reusken, Susan J. M. Hahné, The Dutch ZIKV study team

Published in: Infection | Issue 6/2016

Login to get access

Abstract

Purpose

We report 18 cases of confirmed Zika virus (ZIKV) infection in travellers returning to the Netherlands from Surinam (South America, bordering northern Brazil) and the Dominican Republic.

Methods

In a multi-centre study, we collected epidemiological, virological and clinical characteristics, as well as data on travel history, underlying illness and laboratory results of the 18 imported ZIKV infection cases using a standardised form.

Results

Most cases had a self-limiting course of disease, two patients developed complications, one had Guillain–Barré and another had severe thrombocytopenia. Four patients had underlying illness. One of the reported cases was pregnant. Three of 13 patients tested had a weak-positive result for dengue IgM. The majority of patients were born in Suriname and/or visiting friends and relatives (VFR).

Conclusions

Providing pre-travel advice among travellers, especially VFR travellers, is needed to enhance the use of preventive measures against ZIKV infection. Further evidence on health risks associated with ZIKV infection is urgently needed.
Appendix
Available only for authorised users
Literature
1.
MacKenzie JS, Williams DT. The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health. 2009;56:338–56.CrossRefPubMed
2.
European Centre for Disease Prevention and Control. Rapid Risk Assessment. Zika virus epidemic in the Americas: potential association with microcephaly and Guillain-Barré syndrome. First update, 21 Jan 2016.
3.
4.
European Centre for Disease Prevention and Control. 2016b. Rapid Risk Assessment. Zika virus disease epidemic: potential association with microcephaly and Guillain-Barré syndrome. Fourth update, 9 March 2016.
5.
Mlakar J, Korva M, Tul N, Popović M, Poljšak-Prijatelj M, Mraz J. Zika virus associated with microcephaly. New Engl J Med. 2016;374:951–8.CrossRefPubMed
6.
Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case–control study. The Lancet. 2016;387(10027):1531–9.CrossRef
7.
8.
Zammarchi L, Tappe D, Fortuna C, Remoi ME, Günther S, Venturi G, et al. Zika virus infection in a traveller returning to Europe from Brazil, March 2015. Euro Surveill. 2015;20:14–6.CrossRef
9.
Maria A, Maquart M, Makinson A, Flusin O, Segondy M, Leparc-Goffart I, Le Moing V, Foulongne V. Zika virus infections in three travellers returning from South America and the Caribbean respectively, to Montpellier, France, December 2015 to January 2016. Euro Surveill. 2016;21:2–5.CrossRef
10.
Von Eije KJ, Schinkel J, van den Kerkhof JHCT, Schreuder I, de Jong MD, Grobusch MP, Goorhuis A. Import van ZIKVirus-infectie in Nederland [in Dutch]. Ned Tijdschr Geneeskd. 2016;160:C2895.
11.
Goorhuis A, von Eije KJ, Douma RA, Rijnberg N, van Vugt M, Stijnis C, Grobusch MP. Zika virus and the risk of imported infection in returned travelers: implications for clinical care. Travel Med Infect Dis. 2016;14:13–5.CrossRefPubMed
12.
Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, et al. Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection. The Lancet. 2016;387:939–40.CrossRef
13.
Houghton-Triviño N, Montaña D, Castellanos J. Dengue-yellow fever sera cross-reactivity; challenges for diagnosis. Rev salud publ. 2008;10:299–307.CrossRef
14.
15.
Kramer MA, van Veen MG, de Coul EO, Geskus RB, Coutinho RA, van de Laar MJ, Prins M. Migrants travelling to their country of origin: a bridge population for HIV transmission? Sex Transm Infect. 2008;84:554–5.CrossRefPubMed
16.
Hendel-Paterson B, Swanson SJ. Pediatric travelers visiting friends and relatives (VFR) abroad: illnesses, barriers and pre-travel recommendations. Travel Med Infect Dis. 2011;9:192–203.CrossRefPubMed
17.
Keystone JS. Immigrants returning home to visit friends and relatives (VFRs). Health Inf Int Travel. 2012;547–51.
18.
Chouin-Carneiro T, Vega-Rua A, Vazeille M, Yebakima A, Girod R, Goindin D, et al. Differential Susceptibilities of Aedes aegypti and Aedes albopictus from the Americas to Zika Virus. PLoS Negl Trop Dis. 2016;10:e0004543.CrossRefPubMedPubMedCentral
19.
Tomasello D, Schlagenhauf P. Chikungunya and dengue autochthonous cases in Europe, 2007–2012. Travel Med Infect Dis. 2013;11:274–84.CrossRefPubMed
20.
Hills SL, Russell K, Hennessey M, et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission—continental United States. MMWR Morb Mortal Wkly Rep.2016. ePub: 26 Feb 2016.
Metadata
Title
Zika virus infection in 18 travellers returning from Surinam and the Dominican Republic, The Netherlands, November 2015–March 2016
Authors
Janneke W. Duijster
Abraham Goorhuis
Perry J. J. van Genderen
Leo G. Visser
Marion P. Koopmans
Johan H. Reimerink
Martin P. Grobusch
Annemiek A. van der Eijk
Johannes H. C. T. van den Kerkhof
Chantal B. Reusken
Susan J. M. Hahné
The Dutch ZIKV study team
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 6/2016
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-016-0906-y

Other articles of this Issue 6/2016

Infection 6/2016 Go to the issue

Original Paper

Key priorities in the prevention and control of healthcare-associated infection: a survey of European and other international infection prevention experts

Case Report

Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C

Correspondence

Letter to the editor of infection in response to de Francesco et al., a cluster of invasive listeriosis in Brescia, Italy

Original Paper

A rare cause of infection, Raoultella planticola: emerging threat and new reservoir for carbapenem resistance

Brief Report

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

Original Paper

CAND-LO 2014–15 study: changing epidemiology of candidemia in Lombardy (Italy)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits